

Heterogeneous expression of four MAP kinase isoforms in human tissues

Fernando A. Gonzalez^a, David L. Raden^{a,b}, Mark R. Rigby^{a,b} and Roger J. Davis^{a,b}

^aProgram in Molecular Medicine, Department of Biochemistry and Molecular Biology and ^bHoward Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA

Received 10 February 1992; revised version received 10 April 1992

Mitogen-activated protein kinases (MAP kinases) are a group of closely related enzymes implicated in signal transduction pathways. We report the molecular cloning of four human proteins (p40^{mapk}, p41^{mapk}, p44^{mapk} and p63^{mapk}) with high homology to members of the MAP kinase family. Sequence analysis demonstrated that p44^{mapk} and p63^{mapk} were the products of distinct genes. However, the p40^{mapk} and p41^{mapk} were found to be related, and are likely to result from alternative processing of transcripts from a single gene. The heterogeneous expression of these human MAP kinase isoforms in different tissues may reflect the diversity of signal transduction pathways in differentiated cells.

Signal transduction; Molecular cloning

1. INTRODUCTION

Mitogen-activated protein kinases (MAP kinases) form a family of protein kinases that are activated by numerous extracellular stimuli in many cell types [1–7]. Members of this family of kinases have been implicated in a wide variety of cellular processes. MAP kinases are activated during the M phase of the meiotic cycle [6,8,9] and during mitogenic stimulation of quiescent cells [7,8,10]. It has been shown that MAP kinases can induce reorganization of microtubules in vitro [11], and also may modulate Myc- [12] and Jun- [13] mediated activation of gene expression. Thus, MAP kinases appear to have a fundamental role in multiple cellular processes that may share common signal transduction events [14].

It is believed that MAP kinases play a critical role in a protein kinase cascade pathway of signal transduction [10,15–18]. It has been suggested that MAP kinases represent 'switch' kinases that can transduce a tyrosine protein kinase activity into a serine/threonine protein kinase pathway [19–21]. This is because some MAP kinase isoforms are activated by phosphorylation on tyrosine and threonine [3,9,19–25]. However, the molecular mechanism of MAP kinase activation is unclear. It has been proposed that autophosphorylation plays a role in MAP kinase activation [23–25]. A MAP kinase activator has been identified and partially purified [16,23], and a kinase that phosphorylates MAP kinases may play a role in activation [17]. It is therefore possible that different cell types use related activation pathways in vivo to regulate and control MAP kinase activity [26].

The primary structure of peptide substrates recognized by members of this family of kinases has been examined [27,28] and the consensus for peptide substrate phosphorylation has been defined as Pro-Xaa_n-Ser/Thr-Pro (where Xaa is a neutral or basic amino acid and *n* = 1 or 2). Several proteins have been identified as substrates of MAP kinases. These include: microtubule-associated protein 2 [1,2], myelin basic protein [29], an S6 kinase [10,15,30], the epidermal growth factor receptor [7,31,32], the Myc and Jun proteins [12,13,33], and the kinase itself [21,23–25]. It has been proposed that MAP kinases have 'dual' specificity because they phosphorylate both serine/threonine and tyrosine residues [23–25]. However, it should be noted that the protein tyrosine kinase activity of MAP kinases has been documented only in autophosphorylation experiments, and evidence for the tyrosine phosphorylation of exogenous substrates has not been obtained [23–25].

Several MAP kinase cDNAs have been isolated from rat [4,22], *Xenopus* [8,34] and mouse [35]. Here we report the molecular cloning of four MAP-related protein kinases that are differentially expressed in human tissues. The heterogeneous expression of these MAP kinase isoforms suggests that signal transduction pathways in different tissues may be mediated by specific isoforms of these kinases.

2. EXPERIMENTAL

2.1. Isolation and sequence analysis of p40^{mapk}, p41^{mapk}, p44^{mapk} and p63^{mapk} cDNAs

The oligonucleotide pairs 5'-CAGTACATCGGCCAGGGC-3' (sense)/5'-ATTGGAGGGCTTCAGGTC-3' (antisense) and 5'-TACACCAAATCCATTGAC-3' (sense)/5'-TGTCTCTTGGAAAGATCAG-3' (antisense) were used to amplify the sequences encompassing nucleotides 100–478 and 628–1,069, respectively, from the ERK1 cDNA using the polymerase chain reaction (PCR) and a rat brain

Correspondence address: F.A. Gonzalez, Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01605, USA.

172

Fig. 1D. Nucleotide sequence of p63^{myk} cDNA and its deduced protein sequence. An in-frame termination codon in the sequence 5' to the initiation codon is underlined. The termination codon for the kinase transcripts is represented by three asterisks. Protein sequence sub-domains conserved in protein kinases [37] are double-underlined. The major open reading frame present in this cDNA encodes a predicted protein kinase with a calculated molecular weight of 63 kDa. The protein kinase p63^{myk} contains the sequence SEG (boxed) in place of the TEY autophosphorylation motif present in other members of the MAP kinase family. An in-frame stop codon (TGA) is located 90 bp 5' of the predicted ATG translational initiation codon. Within the long 5' untranslated region there are an additional six potential translational initiation codons. These ATG codons are not located in a favorable context for initiation [36] and correspond to short open reading frames. The significance of the multiple ATG codons in the 5' region of the sequence is discussed in the text.

In order to distinguish the mRNAs encoding p41^{mapk} and p40^{mapk} from each other, we performed Northern blot analysis of poly(A)⁺ mRNA from HeLa cells (Fig. 3). Probes from regions of identity between p41^{mapk} and p40^{mapk} (namely, nucleotides 229–786 and 787–1458 of p41^{mapk}) hybridized with three mRNAs of 5.5, 3.3 and 2.2 kb. In addition, a small (< 1.0 kb) transcript hybridized with one of the probes (nucleotides 787–1458 of p41^{mapk}). A DNA probe that is specific for p40^{mapk} (nu-




Fig. 3. Identification of mRNAs encoding p41^{mapk} and p40^{mapk} in HeLa cells. Northern blots containing 2 µg of poly(A)⁺ mRNA isolated from HeLa cells were hybridized with probes for p41^{mapk}, p40^{mapk} and actin. The probes used are indicated in parentheses as nucleotide numbers. Nucleotides 229–786 of p41^{mapk} correspond to 143–700 of p40^{mapk}, nucleotides 787–1,458 of p41^{mapk} correspond to nucleotides 701–1,372 of p40^{mapk}. RNA size markers (in kb) are shown to the left.

and p44^{mapk}. On the other hand, pancreas expressed only low levels of a transcript that hybridized to the p40/p41^{mapk} probe and did not express detectable levels of p44^{mapk} or p63^{mapk} mRNAs.

Northern blot hybridization with an actin probe revealed that the mRNA preparations were not degraded (Fig. 5D). A ~2.0 kb mRNA was detected in all tissues. An additional actin mRNA (~1.8 kb) was detected in heart and skeletal muscle samples [45]. The pancreas showed the lowest levels of MAP-kinase mRNAs because a substantial fraction of the total mRNA isolated from this tissue encodes two small transcripts, proinsulin and α-amylase.

4. DISCUSSION

This study describes the sequences of four human

Table 1
Comparison between p41^{mapk}, p40^{mapk}, p44^{mapk}, p63^{mapk} and related kinases

	Percent identity			
	p41 ^{mapk} (1–360)	p40 ^{mapk} (1–348)	p44 ^{mapk} (1–355)	p63 ^{mapk} (1–341)
p41 ^{mapk}	100.0			
p42 ^{mapk}	96.9	100.0		
p44 ^{mapk}	84.7	85.9	100.0	
p63 ^{mapk}	39.2	37.9	41.6	100.0
pp42/MAP	98.6	96.8	86.0	41.1
ERK1	84.4	82.2	98.3	41.4
ERK2	98.3	96.8	86.0	41.6
ERK3	41.4	40.8	44.9	72.7
Xp42/MPK1	95.0	92.2	85.1	41.0
KSS1	49.4	51.4	48.9	34.9
FUS3	48.9	51.1	50.0	30.8
CDK2	31.6	35.6	36.2	29.6
hCDC2	28.9	33.3	31.2	26.4

Percentage of amino acid identity between the protein kinase sequences was calculated from computer-generated alignments (MacVector Computer Analysis Software, International Biotechnologies Inc., New Haven, CT). Alignments were made over the residues indicated in parentheses. The protein kinases used in these alignments are: mouse mitogen activated protein kinase, pp42/MAP [35]; rat extracellular signal-regulated kinase 1, ERK1 [4]; rat extracellular signal-regulated kinase 2, ERK2 [22]; rat extracellular signal-regulated kinase 3, ERK3 [22]; *Xenopus* M phase MAP kinase, Xp42/MPK1 [8,34]; *S. cerevisiae* serine/threonine kinases mediating yeast responses to pheromones, KSS1 and FUS3 [38,39]; human cell division kinase 2, CDK2 [40–42]; and human CDC2 protein kinase, hCDC2 [43].

kinases with homology to the MAP family of protein kinases. The existence of a larger family of MAP kinases is supported by the multiplicity of transcripts that specifically hybridized to human MAP kinase probes during Northern analysis (Fig. 5). It is therefore likely that there may be additional MAP kinase-related enzymes in human tissues than the four described here. Indeed the existence of an extended family of MAP kinase isoforms has previously been proposed by Boulton et al. [22].

		Identity
p63 ^{mapk}	MAEKGCDCIASVYGYDLGRFVDFQPLGFGVNGVLVAVDSSRACRKAVVKKIALSDARSMKHALREIKIIRLCHDNIVKVEVLGPKGTDL---QGELEKFSVAYIVQEYMETDLA	113
ERK3	*****FESIMNIH*F*****SYM*LK**C*Q***F*****NDCDKR*I**V*V*P*Q*V*****F*I**S*SQ*TDV*S*TELNSV*****	116
p63 ^{mapk}	RLLEQQTAAEEHAKLFMYQLRGLYIHSANVLHRLKPNIFISTEDLVKIGDFGLARIVDQHYSHKGYLSEGLVTKHYSPRLLLSPNNYTKAIDMWANGCILAENLTGRMIF	229
ERK3	NV**P*L*****R*****L*N*****N*****M*P*****F*****RT**	231
p63 ^{mapk}	AGANELEQMQLILETIPVIREEDKDELLRVMPSEVSSWH-EVKRPLAKLLPEVNSEAIDLEKILITFNMRLTAENGLQHPYMSPYSCPEDEPTSCHPFRIEDEIDIVLMAAQ	344
ERK3	*****S**VH**RQ**S*I*VYIRNDMT*PHK**TQ**CISR**L**Q*****S*****EA*S*****I**F*T**I*S**H**V**L**DETH	347
p63 ^{mapk}	SQLSNWDTCSSRYFVSLSDLEWRPDRCDASEVQDRPGFGLA---EDVQVDPKNDSSSSERFLE---QSHSSMER---AF---EADY---GRSCDYKVGSPSYLDKLLWR	443
ERK3	*HIY**E-----HDCGF*EHD*PIHNF*ID**L**ALSVDVDE*E*****YLDGDR*KY**DPAFDTSY*A*PCMQYDPDH*NK*CDLECSHT*N**TR*****N*V**	459
p63 ^{mapk}	DNKPHHYSEPKLILDLSHMKQAGAPPTATGLADTGAREDPASLFLEIAQHWKSTQCAQSTPARPPTPSAACLPPFPFPFPGGRRRQFPVRFGRVHLPRPEALHQARGPAGQ	557
ERK3	EDEVN*Y*****I**N**EQSKDKSKR*KSKCERNLGVRR*R*KKRPSHHLGRGAKALITL*SSQAFPSVSPVSLT	543

Fig. 4. Comparison of the protein sequence of p63^{mapk} with ERK3. Sequence alignment was computer-generated (MacVector Computer Analysis Software, International Biotechnologies Inc., New Haven, CT) and visually optimized. Asterisks indicate identity to the ERK3 sequence; dashes indicate spaces introduced to optimize sequence alignment. Percent identities for the kinase domain (residues 1–341 in p63^{mapk}) and COOH-terminal domain (residues 342–557 in p63^{mapk}) are presented. The overall sequence identity between p63^{mapk} and ERK3 is 54.6%.

4.1. *p40^{mapk} and p41^{mapk} differ only at their NH₂-termini and a single amino acid in the kinase domain*

Careful examination of the sequences of the p41^{mapk} cDNA and the p40^{mapk} cDNA reveals that the nucleotide sequences are very similar (Fig. 1). In fact nucleotides 200–2351 in the p41^{mapk} cDNA are identical to nucleotides 113–2264 of the p40^{mapk} cDNA except for a single nucleotide replacement. The region of identity between the two sequences includes most of the open reading frame and all of the 3' un-translated region of the p41^{mapk} cDNA (this cDNA does not contain a poly-A tail). In contrast, the 5' region of these cDNAs are different. This results in distinct initiation codons and NH₂-termini of the two protein kinases (Fig. 2). It is possible that the divergent 5' sequences of these two cDNAs are the result of alternative splicing of two different exons corresponding to the 5' untranslated region and the NH₂-terminus to a common set of 3' exons. Previously, this form of alternative expression of isoforms has been described for the *c-abl* protein tyrosine kinase [46]. The *c-abl* gene has alternative promoters with 5' exons that are spliced onto common 3' exons to give rise to two different enzymes, type I and IV kinases that differ only at their NH₂-terminal region [46]. Another example is represented by the human p70 S6 kinase [47]. The cDNA of two forms of the p70 S6 kinase have been isolated that encode divergent 5' regions with alternative potential initiation codons while most of the open reading frame of the two cDNAs is identical [47].

In addition to the divergent NH₂-termini of p41^{mapk} and p40^{mapk}, there is an additional single nucleotide change that replaces Glu⁹¹ (in p41^{mapk}) with Arg (residue 79 in p40^{mapk}). This difference could either be: (i) evidence for additional alternative splicing or editing of a single RNA transcript; (ii) evidence for the presence of a family of related genes that separately encode p41^{mapk} and p40^{mapk}; (iii) caused by a sequence difference in two expressed alleles of the same gene in HeLa cells; or (iv) a cloning artifact. The elucidation of the true genetic relationship between p41^{mapk} and p40^{mapk} must await genomic cloning of these kinases.

4.2. *p63^{mapk} is a novel member of the MAP kinase family*

p41^{mapk} and p40^{mapk} have a high degree of homology with rat ERK2 [22], mouse pp42/MAP [35] and *Xenopus* Xp42/MPK1 [8,34] (see Table I). It is likely that these enzymes are phylogenetic homologs from different species. The protein kinase p44^{mapk} is highly related to ERK1 and these enzymes may therefore also represent phylogenetic homologs. However, although the protein kinase p63^{mapk} is most closely related to ERK3, there is only a 54.6% overall identity between these two enzymes (Fig. 4). Because of the relatively low level of identity it is possible that p63^{mapk} and ERK3 are related enzymes that belong to a sub-family, but may not be true phylogenetic homologs.

The enzymes p63^{mapk} and ERK3 share a unique feature in that they contain the sequence Ser-Pro-Arg in substitution for the Ala-Pro-Glu motif present in the conserved protein kinase sub-domain VIII [37]. In a recent comparison of 154 eukaryotic protein kinases [48] all but one contained a Glu residue within the APE motif (the *S. cerevisiae* PHO85 protein kinase has a conservative substitution of the Glu with Asp). The replacement of Glu with Arg in p63^{mapk} and ERK3 is therefore a distinctive non-conservative change within the protein kinase sub-domain VIII. In contrast, the replacement of Ala in the APE motif with Ser has been found in several other protein kinases [48].

p63^{mapk} and ERK3 differ from most MAP kinases in that the autophosphorylation motif Thr-Glu-Tyr, proposed to be involved in kinase activation, is substituted by Ser-Glu-Gly (see Figs. 1D and 4). This observation raises important mechanistic questions about the physiological regulation of this sub-family of MAP kinases. Investigations of the possible involvement of the SEG sequence in the activation of p63^{mapk} and the examination of alternative regulatory mechanisms of kinase activation are warranted.

The presence of multiple potential initiation codons in the 5' region of the p63^{mapk} open reading frame is intriguing. These upstream ATG codons may reflect an intron-containing mRNA [49]. On the other hand, this 'ATG-burdened' 5' region may impair translation of the p63^{mapk} mRNA in ectopic tissues thereby providing additional regulatory control on the expression of this gene [49].

4.3. *Tissue distribution of human MAP kinases*

Different isoforms of MAP kinases may play diverse roles in signal transduction pathways in different tissues. Our experiments show that the distribution and relative abundance of MAP kinase transcripts are not uniform in human tissues (Fig. 5). Thus, the p63^{mapk} mRNA is more abundant in heart muscle and brain than in any other human tissue tested. On the other hand, the p44^{mapk} mRNA is expressed at high levels in lung tissue, which is rich in fibroblasts, epithelial and endothelial cells.

It is interesting that the three major transcripts (2.8, 4.6 and 5.5 kb) that hybridize to the p40^{mapk}/p41^{mapk} probe do not display the same pattern of expression in all human tissues investigated. Brain, placenta, lung and kidney tissues express a high level of the largest transcript. Heart and skeletal muscle contain all three transcripts, while liver is richer in the 4.6 kb transcript. The multiplicity of transcripts hybridizing to the p40^{mapk}/p41^{mapk} probe may represent: (i) a subfamily of very closely related genes; (ii) alternatively spliced forms of a single transcript, or (iii) expression of transcripts created from different promoters spliced onto common 3' exons.

The discrete pattern of expression of human MAP





A: p40/41^{MAPK}**B: p44^{MAPK}****C: p63^{MAPK}****D: actin**

Fig. 5. Distinct patterns of expression of p40^{mapk}, p41^{mapk}, p44^{mapk} and p63^{mapk} in human tissues. A Northern blot containing 2 µg of poly(A)⁺ mRNA isolated from different human tissues (He, heart muscle; Br, brain; Pl, placenta; Lu, lung; Li, liver; Sk, skeletal muscle; Ki, kidney; Pa, pancreas) was hybridized with probes for (A) p40^{mapk}/p41^{mapk} (nucleotides 787–1,458 of p41^{mapk} that correspond to nucleotides 701–1,372 of p40^{mapk}); (B) p44^{mapk} (nucleotides 7–191); (C) p63^{mapk} (nucleotides 1,673–2,058); and (D) actin. RNA size markers (in kb) are shown to the left of each panel.

kinase mRNAs suggests that different isoforms may play tissue-specific roles. Thus MAP kinases have been implicated in the M phase of the meiotic cycle [6,8,9], in the G₀-to-G₁ progression of quiescent cells [7,8,10], and may play a role in the differentiation of PC-12 cells [50,51]. Human tissues are physiologically regulated by a variety of extracellular factors that may employ a diversity of signal transduction pathways. It is possible that different isoforms of MAP kinases are expressed depending on the signal transduction needs of the differentiated cells present in each tissue.

Acknowledgements: We are grateful to Margaret Shepard for secretarial assistance and Debra A. Latour for technical assistance. This work

was supported, in part, by Grants CA39240 and GM37845 from the National Institutes of Health. F.A.G. is a recipient of a postdoctoral fellowship from the National Science Foundation.

REFERENCES

- [1] Ray, L.B. and Sturgill, T.W. (1987) *Proc. Natl. Acad. Sci. USA* 84, 1502–1506.
- [2] Ray, L.B. and Sturgill, T.W. (1988) *J. Biol. Chem.* 263, 12721–12727.
- [3] Rossomando, A.J., Payne, D.M., Weber, M.J. and Sturgill, T.W. (1989) *Proc. Natl. Acad. Sci. USA* 86, 6940–6943.
- [4] Boulton, T.G., Yancopoulos, G.D., Gregory, J.S., Slaughter, C., Moomaw, C., Hsu, J. and Cobb, M.H. (1990) *Science* 249, 64–67.
- [5] Ahn, N.G., Weil, J.E., Chan, C.P. and Krebs, E.G. (1990) *J. Biol. Chem.* 265, 11487–11494.

- [6] Sanghera, J.S., Paddon, H.B., Bader, S.A. and Pelech, S.L. (1990) *J. Biol. Chem.* 265, 52-57.
- [7] Northwood, I.C., Gonzalez, F.A., Wartmann, M., Raden, D.L. and Davis, R.J. (1991) *J. Biol. Chem.* 266, 15266-15276.
- [8] Posada, J., Sanghera, J., Pelech, S., Aebersold, R. and Cooper, J.A. (1991) *Mol. Cell Biol.* 11, 2517-2528.
- [9] Rossomando, A.J., Sanghera, J.S., Marsden, L.A., Weber, M.J., Pelech, S.L. and Sturgill, T.W. (1991) *J. Biol. Chem.* 266, 20270-20275.
- [10] Sturgill, T.W., Ray, L.B., Erikson, E. and Maller, J.L. (1988) *Nature* 334, 715-718.
- [11] Gotoh, Y., Nishida, E., Matsuda, S., Shiina, N., Kosako, H., Shiokawa, K., Akiyama, T., Ohta, K. and Sakai, H. (1991) *Nature* 349, 251-254.
- [12] Seth, A., Alvarez, E., Gupta, S. and Davis, R.J. (1991) *J. Biol. Chem.* 266, 23521-23524.
- [13] Pulverer, B.J., Kyriakis, J.M., Avruch, J., Nikolakaki, E. and Woodgett, J.R. (1991) *Nature* 353, 670-674.
- [14] L'Allemain, G., Pouyssegur, J. and Weber, M.J. (1991) *Cell Reg.* 2, 675-684.
- [15] Ahn, N. and Krebs, E. (1990) *J. Biol. Chem.* 265, 11495-11591.
- [16] Ahn, N.G., Seger, R., Bratlien, R.L., Diltz, C.D., Tonks, N.K. and Krebs, E.G. (1991) *J. Biol. Chem.* 266, 4220-4227.
- [17] Gomez, N. and Cohen, P. (1991) *Nature* 353, 170-173.
- [18] Campos-Gonzalez, R. and Glenney, J. (1991) *Cell Reg.* 2, 663-673.
- [19] Ray, L.B. and Sturgill, T.W. (1988) *Proc. Natl. Acad. Sci. USA* 85, 3753-3757.
- [20] Anderson, N.G., Maller, J.L., Tonks, N.K. and Sturgill, T.W. (1990) *Nature* 343, 651-653.
- [21] Payne, D.M., Rossomando, A.J., Martino, P., Erickson, A.K., Her, J.-H., Shabanowitz, J., Hunt, D.F., Weber, M.J. and Sturgill, T.W. (1991) *EMBO J.* 10, 885-892.
- [22] Boulton, T.G., Nye, S.H., Robbins, D.J., Ip, N.Y., Radziejewska, E., Morgenbesser, S.D., DePinho, N., Cobb, M.H. and Yancopoulos, G.D. (1991) *Cell* 65, 663-675.
- [23] Seger, R., Ahn, N.G., Boulton, T.G., Yancopoulos, N.P., Radziejewska, L.E., Bratlein, R.L., Cobb, M.H. and Krebs, E.G. (1991) *Proc. Natl. Acad. Sci. USA* 88, 6142-6146.
- [24] Crews, C.M., Alessandrini, A.A. and Erikson, R.L. (1991) *Proc. Natl. Acad. Sci. USA* 88, 8845-8849.
- [25] Wu, J., Rossomando, A.J., Her, J.H., Del Vecchio, R., Weber, M.J. and Sturgill, T.W. (1991) *Proc. Natl. Acad. Sci. USA* 88, 9508-9512.
- [26] Maller, J. (1991) *Curr. Biol.* 1, 334-335.
- [27] Clark-Lewis, I., Sanghera, J.S. and Pelech, S.L. (1991) *J. Biol. Chem.* 266, 15180-15184.
- [28] Gonzalez, F.A., Raden, D.L. and Davis, R.J. (1991) *J. Biol. Chem.* 266, 22159-22163.
- [29] Erikson, A.K., Payne, D.M., Martino, P.A., Rossomando, A.J., Shabanowitz, J., Weber, M.J., Hunt, D.F. and Sturgill, T.W. (1990) *J. Biol. Chem.* 265, 19728-19735.
- [30] Boulton, T.G., Gregory, J.S., Jong, S.M., Wang, L.H., Ellis, L. and Cobb, M.H. (1990) *J. Biol. Chem.* 265, 2713-2719.
- [31] Bird, T.A., Sleath, P.R., deRoos, P.C., Dower, S.K. and Virca, G.D. (1991) *J. Biol. Chem.* 266, 22661-22670.
- [32] Takishima, K., Griswold-Prenner, I., Ingebritsen, T. and Rosner, M.R. (1991) *Proc. Natl. Acad. Sci. USA* 88, 2520-2524.
- [33] Alvarez, E., Northwood, I.C., Gonzalez, F.A., Latour, D.A., Seth, A., Abate, C., Curran, T. and Davis, R.J. (1991) *J. Biol. Chem.* 266, 15277-15285.
- [34] Gotoh, Y., Moriyama, K., Matsuda, S., Okumura, E., Kishimoto, T., Kawasaki, H., Suzuki, K., Yahara, I., Sakai, H. and Nishida, E. (1991) *EMBO J.* 10, 2661-2668.
- [35] Her, J.-H., Wu, J., Rall, T.B., Sturgill, T.W. and Weber, M.J. (1991) *Nucleic Acids Res.* 19, 3743.
- [36] Kozak, M. (1987) *Nucleic Acids Res.* 15, 8125-8148.
- [37] Hanks, S.K., Quinn, A.M. and Hunter, T. (1988) *Science* 241, 42-52.
- [38] Courchesne, W.E., Kunisawa, R. and Thorner, J. (1989) *Cell* 58, 1107-1119.
- [39] Elion, E.A., Grisafi, P.L. and Gink, G.R. (1990) *Cell* 60, 649-664.
- [40] Elledge, S.J. and Spottswood, M.R. (1991) *EMBO J.* 10, 2653-2659.
- [41] Tsai, L.-H., Harlow, E. and Meyerson, M. (1991) *Nature* 353, 174-177.
- [42] Ninomiya-Tsuji, J., Nomoto, S., Yasuda, H., Reed, S.I. and Matsumoto, K. (1991) *Proc. Natl. Acad. Sci. USA* 88, 9006-9010.
- [43] Lee, M.G. and Nurse, P. (1987) *Nature* 327, 31-35.
- [44] Rich, B.E. and Steitz, J.A. (1987) *Mol. Cell Biol.* 7, 4065-4074.
- [45] Pari, G., Jardine, K. and McBurney, M.W. (1991) *Mol. Cell Biol.* 11, 4796-4803.
- [46] Ben-Neriah, Y., Bernards, A., Paskind, M., Daley, G.Q. and Baltimore, D. (1986) *Cell* 44, 577-586.
- [47] Grove, J.R., Banerjee, P., Blasubramanyam, A., Coffey, P.J., Price, D.J., Avruch, J. and Woodgett, J.R. (1991) *Mol. Cell Biol.* 11, 5541-5550.
- [48] Hanks, S.K. (1991) *Curr. Opin. Struct. Biol.* 1, 369-383.
- [49] Kozak, M. (1991) *J. Cell Biol.* 115, 887-903.
- [50] Gomez, N., Tonks, N.K., Morrison, C., Harmar, T. and Cohen, P. (1990) *FEBS Lett.* 271, 119-122.
- [51] Miyasaka, T., Chao, M.V., Sherline, P. and Saltiel, A.R. (1990) *J. Biol. Chem.* 265, 4730-4735.